Evidence Table 161. KQ4—Cmax

| **Author Year****Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change / % change from baseline /****SD /****P Value** | **Between group differences in Means / medians****SD /****P Value** | **Additional comments**  | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Kim 201035Cross-over | ng/mL – measured after single dose of ticlopidine and single dose Ginkgo biloba | Low and/or Moderate | Ticlopidine (250; single dose) | Ginkgo biloba (0.08; single dose) | 24 | Mean: 1071.6SD: 484.1 | GMR: 963.7 | GMRdiff: 1.03Lower: 0.92Upper: 1.16 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 24 | Mean: 1027.0SD: 437.2 | GMR: 932.6 |
| Hadja 201028Cross-over | µg/L | Low (healthy men) | Simvastatin(20) | Garlic (600 mg twice daily) | 10 | Mean: 5.25SD: 6.32 | - | - | - | Medium |
| No treatment | 10 | Mean: 3.85SD: 1.99 | - | - | - | Medium |
| Hadja 201028Cross-over | µg/L | Low (healthy men) | Pravastatin(20) | Garlic (600 mg twice daily) | 10 | Mean: 14.2SD: 6.7 | - | - | - | Medium |
| No treatment | 10 | Mean: 18.8SD: 12.2 | - | - | - | Medium |
| Tankanow 200365Cross-over | ng/mL: Measured after 10 days digoxin or 21 days digoxin + hawthorn | Low (healthy) | Digoxin (0.25) | Hawthorn (0.9) | 8 | Mean: 1.80SD: 0.20 | - | - | - | Medium |
| No treatment | 8 | Mean: 2.10SD: 0.60 | - |
| Mauro 200343Cross-over | ng/mL; Measured after single-dose administration of digoxin following 7 days pre-treatment with Ginkgo biloba or no pre-treatment | Low (healthy) | Digoxin (0.5; single dose) | *Ginkgo biloba* (0.24) | 8 | Mean: 1.4SD: 0.5 | - | - | - | Medium |
| No treatment | 8 | Mean: 1.6SD: 0.3 | - |

| Evidence Table 161. KQ4—Cmax (continued) |
| --- |
| **Author Year****Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional comments**  | **Overall Risk of Bias (ROB) Assessment** |
| Jiang 200433Cross-over | R-Warfarin:µg/mL; measured after single dose warfarin following 1 week pretreatment with ginseng or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 1.89SD: 0.29Lower: 1.70Upper: 2.00 | - | GMRdiff: 0.98Lower: 0.88Upper: 1.09 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.92SD: 0.32Lower: 1.70Upper: 2.10 | - |
| S-Warfarin:µg/mL; measured after single-dose warfarin following 1 wk pretreatment with ginseng or no pretreatment. Subjects followed for 1 wk post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 1.93SD: 0.31Lower: 1.70Upper: 2.10 | *-* | GMRdiff:1.01Lower: 0.90Upper: 1.12 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.89SD: 0.26Lower: 1.70Upper: 2.00 | *-* |
| Jiang 200532Cross-over | R-Warfarin:µg/mL; measured after single dose warfarin following 1 week pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean:1.70Lower: 1.50Upper: 1.90 | - | GingerGMRdiff: 1.02Lower: 0.95Upper: 1.07Ginkgo bilobaGMRdiff: 1.03Lower: 0.97Upper:1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
|  |  |  | Ginkgo biloba(12)  | 12 | Mean: 1.80Lower: 1.50Upper: 2.00 | - |  |  |
| No treatment | 12 | Mean: 1.70Lower: 1.40Upper: 2.00 | - |  |
| S-Warfarin:µg/mL; measured after single-dose warfarin following 1 wk pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for 1 wk post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean: 1.70Lower: 1.50Upper: 2.00 | - | GingerGMRdiff:1.01Lower: 0.94Upper:1.07Ginkgo bilobaGMRdiff:1.04Lower: 0.97Upper:1.09 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| *Ginkgo biloba* (12) | 12 | Mean:0.12Lower: 0.11Upper: 0.13 | - |
| No treatment | 12 | Mean:0.12Lower: 0.11Upper: 0.14 |  |
| Gosai 200826Cross-over | ng/mL; 2 weeks treatment | Low (healthy) | Rovustatin (40) | Omega-3 fatty acids (EPA, DHA or both) (4) | 42 | Mean: 25.51SD: 11.75 | - | GMRdiff: 1.01Lower: 0.94Upper: 1.09 | % coefficient of variation:Omega-3: 46.08Control: 34.85Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 41 | Mean: 24.3SD: 8.47 | - |
| Di Spirito 200819Cross-over | Atorvastatin; Day 14 steady state (ng/mL); 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 52.1SD: 62 | - | GMRdiff: 1.03Lower: 0.93Upper: 1.14 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 50.9SD: 51 | - |
| 2-hydroxytorvastatin; Day 14 steady state; (ng/mL); 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 45SD: 59.3 | - | GMRdiff: 0.95Lower: 0.85Upper: 1.06 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 47.6SD: 50 | - |
| Mohammed Abdul 200849Cross-over | R-Warfarin:µg/mL; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 1.9Lower: 1.5Upper: 2.2 | - | GMRdiff: 1.02Lower: 0.80Upper:1.40 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.8Lower: 1.7Upper: 2.0 | - |
| S-Warfarin:µg/mL; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 1.9Lower: 1.5Upper: 2.2 | - | GMRdiff: 1.06Lower: 0.70Upper:1.47 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.8Lower: 1.7Upper: 1.9 | - |
| McKenney 200645Cross-over | Simvastatin; Cmax over final dosing interval (ng/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 24 | Mean: 15.4SD: 7.6 | - | - | - | Medium |
| No treatment | 23 | Mean: 13.5SD: 6.1 | - |
| Beta-hydroxy simvastatin; Cmax over final dosing interval (ng/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 24 | Mean: 6.1SD: 3.6 | - | - | - | Medium |
| No treatment | 23 | Mean: 6.1SD: 3.2 | - |
| Abdul 20101Cross-over | R-Warfarin:µg/mL (1 hour); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose.  | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean:1.20Lower: 1.10Upper: 1.40 | - | GMRdiff: 0.98Lower: 0.88Upper: 1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment  | 12 | Mean: 1.30Lower: 1.10Upper: 1.50 | - |
| S-Warfarin:µg/mL (1 hour); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean: 1.30Lower: 1.10Upper: 1.43 | - | GMRdiff: 0.97Lower: 0.86Upper: 1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment  | 12 | Mean: 1.30Lower: 1.10Upper: 1.60 | - |